Design and Development of Data-Driven AI to Reduce the Discrepancies in Healthcare EHR Utilization

Purpura fulminans, a rare but life-threatening manifestation of disseminated intravascular coagulation, presents a formidable challenge in critical care settings, particularly when complicated by sepsis.Past research has underscored the crucial role of timely and appropriate antimicrobial therapy in mitigating mortality and morbidity in purpura fulminans-associated sepsis.However, gaps persist in our understanding of the optimal selection, dosing, and duration of antimicrobial agents in this context.This review examines existing literature on antimicrobial therapy in purpura fulminans-associated sepsis, highlighting advancements in antimicrobial pharmacokinetics, pathogen susceptibility patterns, and the evolving landscape of antimicrobial resistance.Additionally, it discusses emerging strategies such as combination antimicrobial therapy, adjunctive therapies targeting virulence factors, and antimicrobial stewardship interventions aimed at optimizing antimicrobial use while minimizing collateral damage.Future research directions include prospective studies evaluating personalized antimicrobial regimens guided by pharmacokinetic/pharmacodynamic principles, the role of novel antimicrobial agents, and the impact of antimicrobial therapy on long-term outcomes such as antimicrobial resistance and microbiome dysbiosis.Moreover, the integration of rapid diagnostic technologies and biomarker-guided approaches holds promise for tailoring antimicrobial therapy to individual patient characteristics and disease severity, ultimately enhancing clinical outcomes in purpura fulminans-associated sepsis within critical care settings.